<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066651</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000316451</org_study_id>
    <secondary_id>NCI-03-C-0243</secondary_id>
    <secondary_id>NCI-6221</secondary_id>
    <secondary_id>NCI-SS1PE-002</secondary_id>
    <nct_id>NCT00066651</nct_id>
    <nct_alias>NCT00065481</nct_alias>
  </id_info>
  <brief_title>Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells.&#xD;
      Immunotoxin therapy may be effective in treating advanced solid tumors.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of immunotoxin therapy&#xD;
      in treating patients with recurrent unresectable advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of SS1(dsFv)-PE38 immunotoxin in patients with&#xD;
           advanced mesothelin-expressing malignancies.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the plasma pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the response in patients treated with this drug.&#xD;
&#xD;
        -  Correlate the induction of antibody against this drug with its pharmacokinetics in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive a test dose of SS1(dsFv)-PE38 immunotoxin IV over 1-2 minutes on day 1&#xD;
      followed by SS1(dsFv)-PE38 immunotoxin IV over 30 minutes on days 1, 3, and 5. Treatment&#xD;
      repeats every 4 weeks for up to 3 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of SS1(dsFv)-PE38 immunotoxin until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Cervical Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Malignant Mesothelioma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SS1(dsFv)-PE38 immunotoxin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced malignancy of 1 of the following types:&#xD;
&#xD;
               -  Ovarian cancer&#xD;
&#xD;
                    -  All nonmucinous epithelial histologies are eligible&#xD;
&#xD;
               -  Primary peritoneal cavity cancer&#xD;
&#xD;
               -  Fallopian tube cancer&#xD;
&#xD;
               -  Malignant mesothelioma&#xD;
&#xD;
                    -  No sarcomatous histology&#xD;
&#xD;
               -  Pancreatic cancer&#xD;
&#xD;
               -  Squamous cell cancer (SCC) of the lung&#xD;
&#xD;
               -  SCC of the cervix&#xD;
&#xD;
               -  SCC of the head and neck&#xD;
&#xD;
          -  Recurrent unresectable disease, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Previously treated with definitive standard therapy&#xD;
&#xD;
               -  Patient refused prior standard therapy&#xD;
&#xD;
          -  Initial or recurrent tumor positive (at least 30% of tumor cells) for mesothelin by&#xD;
             immunohistochemistry* NOTE: *Immunohistochemical evaluation not required for patients&#xD;
             with pancreatic cancer&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No clinically significant pericardial effusion&#xD;
&#xD;
          -  No known CNS or spinal cord involvement by tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Albumin at least 3.0 g/dL&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
               -  Seropositive allowed if clinically asymptomatic&#xD;
&#xD;
          -  except if clinically asymptomatic and bilirubin and AST and ALT meet the outlined&#xD;
             criteria&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
          -  Calcium no greater than ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class II-IV cardiovascular disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Oxygen saturation at least 93% on room air&#xD;
&#xD;
          -  DLCO at least 50% of predicted*&#xD;
&#xD;
          -  Total lung capacity and vital capacity at least 50% of predicted*&#xD;
&#xD;
          -  FEV_1 at least 50% of predicted* NOTE: *For patients with pleural mesothelioma and as&#xD;
             clinically indicated&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No infection requiring parenteral antibiotics&#xD;
&#xD;
          -  No HIV infection&#xD;
&#xD;
          -  Serum neutralizing activity to SS1(dsFv)-PE38 immunotoxin (at 200 ng/mL) no greater&#xD;
             than 75%&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior therapy and recovered&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raffit Hassan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2006</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>ovarian carcinosarcoma</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian mixed epithelial carcinoma</keyword>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>Brenner tumor</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>epithelial mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

